Arvelle Therapeutics, a biopharmaceutical company involved in bringing innovative treatments to the patients of CNS disorders, has moved into a partnership with a pharmaceutical supplying firm Durbin Group (Durbin) in order to process the cenobamate distribution with the help of Managed Access Program (MAP). If a physician-assessed clinical necessitates their treatment, the MAP patients who are drug-resistant focal onset seizures would be eligible for the treatment with cenobamate before its commercial availability.

The company was receving higher number of requests by European epileptologists for the access to cenobamate which stayed the unmet demand. So the company partnered with a pan-European regulatory expertise group to allow MAP distribution.

Cenobamate is a new antiseizure medication (ASM) approved by FDA for the treatment of partial-onset seizures in adults. SK Biopharmaceuticals and SK life science discovered the this ASM.

Previously in early 2019, SK Biopharmaceuticals moved into an exclusive licensing agreement with Arvelle Therapeutics for the development and commercialization of cenobamate in Europe.

Arvelle Therapeutics Co-Founder and Chief Medical Officer, Ilise Lombardo MD said, “Over the past months we have received requests by European epileptologists with requests for access to cenobamate, indicating a high unmet need. As a result of increasing requests, we have selected a partner with extensive pan-European experience and regulatory expertise to support us with the MAP distribution. We are very pleased to partner with Durbin on this program.”

Arvelle Therapeutics which is a emerging biopharmaceutical company working on innovative solutions to provide the patients suffering from CNS disorders. While Durbin a global specialist medical suppliers and a part of Uniphar Group’s Product Access division.